Archive | Redefining Every Stage Investments (RESI) RSS feed for this section

Hot Mandate: Canada Based VC Invests In Therapeutics, Medical Devices & AI/Digital Health, With Special Interest in Precision Medicine & AI in Therapeutics Development

5 Feb

A venture capital firm with multiple offices in Canada recently launched a $200M (CAD) fund, through which the firm will invest around 80% in Canada-based life science companies and 20% in USA/global companies. The firm will generally participate in Series A financing rounds and beyond, including crossover and IPO; average check sizes will be around $5-10M CAD, with a total of $15-20M CAD will be reserved for follow-on investments. In addition, the firm is also dedicated to company incubation and creation for which the firm will work with earlier stage companies and deploy smaller amounts of capital (around $1M CAD).

The firm has a general theme of investing in precision medicine – technologies that can enhance the quality and accuracy of diagnoses, enable more precise and personalized treatments, targeted therapies such as cell & gene therapy, technologies that leverage AI to accelerate therapeutic development, etc. In terms of sector, the firm seeks to invest 50-60% in therapeutics, 20-30% in medical devices, and 10-15% in AI/digital health/diagnostics. For medical devices, the firm prefers later stage opportunities that are close to commercialization. The firm does not focus on any particular indication area.

The firm does not have specific company or management team requirements. While the firm likes to see management teams with a successful track record and wide range of experiences, this is not required and the firm is open to working on inexperienced management teams. The firm is capable of leading or co-leading investment rounds, and is also open to co-investing with likeminded investors. The firm is very hands-on and leverages their network to actively support the growth of their portfolio companies and provide needed resources.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

Hot Mandate: Hong Kong Based boutique VC Invests in All Sectors of Healthcare Technologies, Most Interested In Areas Including AI In Medtech

5 Feb

A boutique venture capital firm founded in 2015 in Hong Kong currently manages a 150M USD fund and a 200M RMB fund. The fund is industry agnostic within China while it focuses only on healthcare ex-China. The firm generally participates in Series A or B rounds but would also consider seed and growth-stage funding. Typical equity investment size ranges from $1-5M. The firm is open to both leading and co-investing, and is actively seeking new opportunities from across the world with a focus on companies in China, U.S., Europe, and Israel. The firm helps portfolio companies get into massive and fast-growing markets of China and Asia, and assists Chinese companies to expand abroad.

The firm is opportunistic across all subsectors of healthcare. Within MedTech, the firm is most interested in medical devices, artificial intelligence, robotics, and mobile health. The firm is seeking post-prototype innovations that are FDA cleared or are close to receiving clearance. Within therapeutics,

the firm is interested in therapeutics for large disease markets such as oncology, neurology, and metabolic diseases. The firm is open to all modalities with a special interest in immunotherapy and cell therapy.

The firm is in search of ambitious companies with strong, experienced management teams and takes a hands-on approach to portfolio companies and can work with incomplete teams and can contribute expertise in essential services: branding, marketing, channel development, overseas expansion, human resources and finance. The firm may also request distribution or negotiation rights in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

Fill Your Fundraising Dance Card with These Investors

4 Feb

By Rory McCann, Marketing Manager & Conference Producer, LSN

For more than eight years, Life Science Nation (LSN) has hosted the go-to partnering events that have provided attendees with what they seek most, but rarely get with networking conferences: a well-matched meeting. LSN’s premier partnering system has helped raise millions of dollars for early-stage companies in life science and healthcare by matching fundraising founders with investors and strategic partners based on product fit and stage of development.

Healthtech Partnering Week (HPW), March 15-19 is right around the corner, and we are thrilled to host enthusiastic, active investors and service providers passionate about advancing products and services that help patients live well. Check out our growing list of confirmed investors joining us and sign up by February 19 to save on our early bird rates.

Confirmed HPW Investors

Confirmed RESI Investors Confirmed 4D Meets AI Investors Confirmed LHI Investors

 

 

Healthtech Partnering Week March Schedule

4 Feb

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claireHealthtech Partnering Week, the premier partnering experience for early-stage companies innovating life science and healthcare, is fast approaching! We are thrilled to announce the schedule for the week. If you haven’t signed up yet, there’s still time to save on early bird rates – sign up by February 19 to save and start meeting your fundraising goals!

Check Out Our Live Panel Schedule for Healthtech Partnering Week, March 15-19

Digital RESI

Digital Redefining Early Stage Investments (RESI) is Life Science Nation’s flagship partnering event, featuring active, early-stage investors across biotech, medtech, and healthtech. RESI seeks to highlight the latest investment trends in order to advance cross-border, cross-domain partnerships.

Time (EST) Monday, March 15 Tuesday, March 16 Wednesday, March 17
10:00 AM Early Stage Therapeutics Investors Panel Diagnostics Investors Panel Tools and R&D Services Panel
1:00 PM Innovator’s Pitch Challenge Session I Innovator’s Pitch Challenge Session III Innovator’s Pitch Challenge Session V
2:00 PM Medical Devices Investors Panel Combination Devices Panel Digital Health Panel
3:00 PM Innovator’s Pitch Challenge Session II Innovator’s Pitch Challenge Session IV Innovator’s Pitch Challenge Session VI
4:00 PM Digital Therapeutics Panel Cell & Gene Therapy Panel

4D Meets AI

4D Meets AI panels host active investors and their portfolio companies to discuss funding, partnerships, and the future of AI in each one of the 4Ds: drugs, devices, diagnostics, and digital health.

Time (EST) Thursday, March 18 Friday, March 19
9:00 AM Drugs Panel Diagnostics Panel
1:00 PM Innovator’s Pitch Challenge Session I Innovator’s Pitch Challenge Session II
2:00 PM Devices Panel Digital Health Panel
More Content Panels to Come
Stay Tuned for the 4D Meets AI Workshops

Longevity, Health & Innovation

Longevity, Health & Innovation features two tracks: Investment Ecosystem and Market Overview. The panels, co-organized with Mary Furlong & Associates are designed to provide a whole picture of the longevity marketplace, focusing on early-stage investments and strategic partnerships, as well as technology, innovation, regulation, and advancements in the field.

Time (EST) Thursday, March 18 Friday, March 19
10:00 AM Digital Health for the Elderly Panel Investing in New, Now, and Next Panel
11:00 AM Early Detection of CNS Disorders Panel Therapeutics for Thriving Panel
12:00 PM Innovator’s Pitch Challenge Session I Innovator’s Pitch Challenge Session II
3:00 PM Stakeholders in the Longevity Marketplace Panel Investors and Entrepreneurs Share the Latest Trends Panel
4:00 PM Care Economy Panel Health Technology Panel

Introducing the Age-Tech Bulletin Newsletter

4 Feb

By Shelly Mittal, Investor Research Analyst, LSN

Life Science Nation (LSN) is thrilled to announce the Age-Tech Bulletin, a weekly newsletter featuring investors and strategic partners seeking to invest in early-stage senior healthcare and longevity companies. This newsletter provides the latest investment mandates, enabling fundraising CEOs to connect with strategic partners active in their industry. Age-Tech Bulletin also provides opportunities for investors, fundraising CEOs, and strategic partners to get involved with the Longevity, Health & Innovation (LHI) digital partnering conference: a unique partnering experience, co-organized with Mary Furlong & Associates, connecting longevity industry leaders with promising age-tech companies.

The Age-Tech Bulletin highlights networking opportunities exclusively available through our industry leaders, connecting investors and start-ups to facilitate early-stage deals for seniors to live longer and healthier lives.

Check out our most recent issue and sign up to receive the weekly Age-Tech Bulletin and find out how to get involved with Longevity, Health & Innovation, March 18-19, 2021.

Hot Investor Mandate: Asia Venture Capital Fund Invests Up to $25M in Therapeutics & Medical Device Companies with Strong Interest in Oncology, Immunology, CNS

4 Feb

A life sciences venture capital fund headquartered in Asia is actively seeking investment opportunities. On average, the size of investment is $5-25M in venture rounds. The firm prefers to act as the lead investor but is also open to co-investing. The firm looks for companies located around the globe, with a preference in the US and China. The firm is actively seeking new investment opportunities.

The firm is focused on Therapeutics and Medical Devices opportunities. The firm’s core focused therapeutic areas include oncology, immunology and CNS diseases, but is also opportunistic in other indications (modality agnostic) and willing to consider orphan indications. The firm is also interested in interventional, novel medical devices in cardiovascular, neuro-vascular diseases.

The firm prefers management team with strong scientific background and expertise, successful track records would be a plus but is not required. The firm generally takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA VC Firm Invests Up to $50M in Growth Stage, Revenue Generating Companies with Strong Marketplace Validation

4 Feb

A USA-based firm makes equity investments in commercial stage (post regulatory approval) healthcare companies with meaningful revenue and traction. The firm typically invests between $15-$50m per company.

The firm invests exclusively in healthcare and is open to all sub-sectors within the industry. That said, the firm does not invest in pre-revenue companies or those with regulatory risk; investments are made in revenue-generating companies with products that have already received regulatory approval or which do not require regulatory approval. The firm looks for companies with meaningful marketplace validation and growing revenues, where the firm’s investment could help to accelerate the adoption.

The firm prefers to invest in management teams with experience in leading and growing businesses of scale and relevant industry experience.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →